menu
    • menu
    [{"orgOrder":0,"company":"Kedalion Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Lifitegrast","moa":"LFA-1","graph1":"Ophthalmology","graph2":"Approved","graph3":"Kedalion Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kedalion Therapeutics \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Kedalion Therapeutics \/ Novartis"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"Bausch & Lomb Incorporated","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Bausch & Lomb Incorporated","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bausch & Lomb Incorporated \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Bausch & Lomb Incorporated \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Lifitegrast","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Novartis Pharmaceuticals Corporation","amount2":2.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":2.5,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"12","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bausch & Lomb Incorporated"}]

    Find Clinical Drug Pipeline Developments & Deals for Lifitegrast

    Menu

    Lifitegrast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Novartis Completes Divestment of ‘Front of Eye’ Ophthalmology Assets

                            Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                            Brand Name : Xiidra

                            Molecule Type : Small molecule

                            Upfront Cash : $1,750.0 million

                            September 29, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bausch & Lomb Incorporated

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Bausch & Lomb Incorporated

                            Canada arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®

                            Details : The financing will fund the acquisition Xiidra (lifitegrast ophthalmic solution), a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalm...

                            Brand Name : Xiidra

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 11, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Novartis Signs Agreement to Divest Front of Eye Ophthalmology Assets in Line with Focused Strategy

                            Details : Novartis will focus on other therapeutic areas, like retinal diseases via platforms including gene therapy and optogenetics through divestment of Xiidra (lifitegrast), the first approved treatment for dry eye disease, and SAF312 (libvatrep), for chronic ...

                            Brand Name : Xiidra

                            Molecule Type : Small molecule

                            Upfront Cash : $1,750.0 million

                            June 30, 2023

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Bausch & Lomb Incorporated

                            Deal Size : $2,500.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kedalion Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kedalion Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Acquires Kedalion Therapeutics and Its Innovative Ocular Delivery Platform that Could Transform Patie...

                            Details : Novartis intends to develop the AcuStream technology for potential use with its existing and future front-of-eye therapies, which could include Xiidra® (lifitegrast ophthalmic solution) 5%, a first-in-class prescription LFA 1 antagonist for the treatmen...

                            Brand Name : Xiidra

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 30, 2022

                            Lead Product(s) : Lifitegrast

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth